Article -> Article Details

Market Overview

The global Transthyretin Amyloidosis Treatment Market size was valued at USD 6.94 Billion in 2024. The market is anticipated to grow at a CAGR of 11.60% during the forecast period 2025-2033 to reach USD 20.35 Billion by 2033. Growth is driven by advances in targeted therapies, increased disease diagnosis, rising geriatric populations, adoption of RNA-based and combination therapies, and patient-centric care models.

Study Assumption Years

• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Period: 2025-2033

Transthyretin Amyloidosis Treatment Market Key Takeaways

• The market size was USD 6.94 Billion in 2024 with a forecast CAGR of 11.60% through 2025-2033.
• North America leads with a market share of over 46.3% in 2024.
• Targeted therapies accounted for 85.6% market share in 2024.
• ATTR with polyneuropathy (ATTR-PN) held 78.1% market share among types.
• Wild-type amyloidosis dominates the disease segment with 56.2% share.
• Hospital pharmacies represented 48.6% of distribution channel market share in 2024.

Sample Request Link: https://www.imarcgroup.com/transthyretin-amyloidosis-treatment-market/requestsample

Market Growth Factors

Advancements in Targeted Therapies: Targeted therapies are set to dominate the market with a whopping 85.6% share in 2024, as they tackle the underlying causes of ATTR head-on. Medications like patisiran, vutrisiran, and tafamidis work their magic by either silencing the expression of problematic genes or stabilizing transthyretin proteins, which helps slow down disease progression and enhances patient outcomes. Ongoing investments in pharmaceutical research and development, along with genetic studies, are fueling growth in this area.

Increasing Diagnosis and Aging Population: ATTR mainly impacts older adults, particularly those over 60. With the global population aging, the number of individuals at risk is on the rise—by 2030, one in six people will be over 60, and this figure is expected to double to 2.1 billion by 2050. Thanks to advancements in diagnostics, including genetic testing and cutting-edge imaging techniques, we can now identify hereditary and wild-type ATTR more accurately and earlier, which broadens the pool of patients who can receive treatment.

Adoption of RNA-Based and Combination Therapies: RNA interference (RNAi) treatments, such as vutrisiran, have shown impressive results, cutting down deaths and cardiovascular events by 28%. These therapies work by silencing the genes that lead to faulty protein production. Additionally, combination therapies that blend TTR stabilizers with RNA-based drugs (like patisiran and tafamidis) are gaining popularity, as they provide synergistic effects in managing the disease and improving patient outcomes, paving the way for broader adoption of these innovative treatments.

Market Segmentation

Analysis by Therapy:

• Targeted Therapy: The largest market segment (85.6% in 2024), featuring innovative RNA-based drugs (patisiran, vutrisiran) and protein stabilizers (tafamidis) that address disease causality.
• Supportive Therapy: Present but no specific data provided.
• Pipeline Therapy: Mentioned but no detailed data available.

Analysis by Type:

• ATTR with Polyneuropathy (ATTR-PN): Leading type with 78.1% market share in 2024, driven by high hereditary prevalence and debilitating nerve damage symptoms.
• ATTR with Cardiomyopathy (ATTR-CM): Included in type segmentation but no explicit market share stated.

Analysis by Disease:

• Wild-Type Amyloidosis: Largest share at 56.2% in 2024, largely due to aging population prevalence and improvements in diagnostic detection.
• Hereditary Transthyretin Amyloidosis: Present as a disease category but no quantified share.

Analysis by Distribution Channel:

• Hospital Pharmacies: Dominant channel with 48.6% market share in 2024, critical for initiating complex treatments.
• Specialty Pharmacies, Retail Pharmacies, Online Pharmacies: Listed but no explicit data available.

Regional Insights

North America dominates the market with over 46.3% share in 2024. Growth in this region is propelled by advanced healthcare infrastructure, rising awareness, greater adoption of novel and RNA-based therapies, and supportive reimbursement policies. The United States holds 78.60% share within North America, driven by FDA approvals (e.g., BridgeBio's Attruby) and extensive clinical trials enhancing ATTR management.

Recent Developments & News

• In October 2024, Alnylam Pharmaceuticals submitted a supplemental New Drug Application to the FDA for vutrisiran (AMVUTTRA) targeting ATTR-CM.
• In September 2024, AstraZeneca's Alexion division received FDA fast track designation for ALXN2220, a treatment for transthyretin amyloidosis with cardiomyopathy.

Key Players

• Akcea Therapeutics, Inc
• Alnylam Pharmaceuticals, Inc.
• AstraZeneca
• BridgeBio, Inc.
• Intellia Therapeutics, Inc
• Pfizer Inc

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request For Customization: https://www.imarcgroup.com/request?type=report&id=27702&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201971-6302